Management of Pedal Edema in Elderly Male with Stage 3b CKD

Patient Assessment and Monitoring

• The American Journal of Kidney Diseases recommends verifying blood pressure is at goal (<130/80 mm Hg for CKD patients) 3
• Document current pedal edema grade (0-4 scale) and compare to baseline before medication change, as suggested by Praxis Medical Insights 1
• Measure current weight and compare to weight when edema was at its worst, according to Praxis Medical Insights 1, 2
• Check basic metabolic panel today (electrolytes, creatinine, eGFR) since HCTZ was recently initiated, as recommended by the American Journal of Kidney Diseases 3

Medication Management

• The American Journal of Kidney Diseases suggests that HCTZ is appropriate for stage 3b CKD (eGFR 30-44 mL/min/1.73 m²) 3
• The combination of HCTZ with losartan (ARB) is ideal for CKD patients, providing both blood pressure control and renoprotection, according to the American Journal of Kidney Diseases and Mayo Clinic Proceedings 3, 5
• Do not restart the discontinued medication, as the improvement in edema confirms it was the culprit, as noted by Praxis Medical Insights 1, 2

Dietary Counseling and Follow-Up

• Confirm fluid restriction to 1 liter daily is appropriate for stage 3b CKD with history of edema, as recommended by Praxis Medical Insights 2
• Sodium restriction (<2 grams/day) is critical for edema control and blood pressure management in CKD, according to the American Journal of Kidney Diseases 3
• Repeat basic metabolic panel in 2-4 weeks to reassess electrolytes and kidney function after HCTZ stabilization, as suggested by the American Journal of Kidney Diseases 3

Critical Pitfalls to Avoid

• Do not empirically increase diuretic dose without first confirming adequate dietary sodium restriction and fluid compliance, as warned by Praxis Medical Insights 2
• Do not attribute all edema to medications without ruling out heart failure, especially given the patient's age and multiple cardiovascular risk factors, as cautioned by Praxis Medical Insights 1, 2
• Monitor potassium closely given the patient is on both HCTZ (potassium-wasting) and losartan (potassium-sparing), plus KCL ER supplementation, as advised by the American Journal of Kidney Diseases 3